WO2010040572A3 - Antibodies against h5n1 influenza viruses - Google Patents

Antibodies against h5n1 influenza viruses Download PDF

Info

Publication number
WO2010040572A3
WO2010040572A3 PCT/EP2009/007631 EP2009007631W WO2010040572A3 WO 2010040572 A3 WO2010040572 A3 WO 2010040572A3 EP 2009007631 W EP2009007631 W EP 2009007631W WO 2010040572 A3 WO2010040572 A3 WO 2010040572A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies against
influenza viruses
antibodies
fragments
vaccination
Prior art date
Application number
PCT/EP2009/007631
Other languages
French (fr)
Other versions
WO2010040572A2 (en
Inventor
Alessandro Ascione
Maurizio Cianfriglia
Michela Flego
Original Assignee
Istituto Superiore di Sanità
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Superiore di Sanità filed Critical Istituto Superiore di Sanità
Publication of WO2010040572A2 publication Critical patent/WO2010040572A2/en
Publication of WO2010040572A3 publication Critical patent/WO2010040572A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided are antibodies, or fragments thereof, useful in recognising multiple clades of H5N1 avian influenza virus and methods of immunotherapy and vaccination comprising said antibodies or fragments.
PCT/EP2009/007631 2008-10-07 2009-10-07 Antibodies WO2010040572A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0818356A GB0818356D0 (en) 2008-10-07 2008-10-07 Antibodies
GB0818356.8 2008-10-07

Publications (2)

Publication Number Publication Date
WO2010040572A2 WO2010040572A2 (en) 2010-04-15
WO2010040572A3 true WO2010040572A3 (en) 2010-08-19

Family

ID=40042419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/007631 WO2010040572A2 (en) 2008-10-07 2009-10-07 Antibodies

Country Status (2)

Country Link
GB (1) GB0818356D0 (en)
WO (1) WO2010040572A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3634459A4 (en) * 2017-02-10 2021-01-06 Washington University Antibodies to tip1 and methods of use thereof
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN113121680B (en) * 2021-04-12 2022-03-29 华南农业大学 H5 subtype avian influenza resisting nano antibody protein and encoding gene and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089753A2 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008033105A1 (en) * 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
WO2008110937A2 (en) * 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089753A2 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008033105A1 (en) * 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
WO2008110937A2 (en) * 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ASCIONE A ET AL: "Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 83, no. 3, 1 September 2009 (2009-09-01), pages 238 - 244, XP026448136, ISSN: 0166-3542, [retrieved on 20090527] *
FLEGO MICHELA ET AL: "Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach", BMC INFECTIOUS DISEASES, BIOMED CENTRAL, LONDON, GB, vol. 5, no. 1, 19 September 2005 (2005-09-19), pages 73, XP021004134, ISSN: 1471-2334 *
KASHYAP ARUN K ET AL: "Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 105, no. 16, 22 April 2008 (2008-04-22), pages 5986 - 5991, XP002488075, ISSN: 0027-8424 *
LIM ANGELINE PC ET AL: "Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, vol. 5, no. 1, 11 July 2008 (2008-07-11), pages 80, XP021038387, ISSN: 1743-422X *
SIMMONS CAMERON P ET AL: "Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza.", May 2007, PLOS MEDICINE MAY 2007, VOL. 4, NR. 5, PAGE(S) E178, ISSN: 1549-1676, XP002568898 *
VITI F ET AL: "DESIGN AND USE OF PHAGE DISPLAY LIBRARIES FOR THE SELECTION OF ANTIBODIES AND ENZYMES", METHODS IN ENZYMOLOGY; [METHODS IN ENZYMOLOGY], ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 326, 1 January 2000 (2000-01-01), pages 480 - 505, XP008079779, ISSN: 0076-6879 *

Also Published As

Publication number Publication date
GB0818356D0 (en) 2008-11-12
WO2010040572A2 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
WO2009121004A3 (en) Neutralizing molecules to viral antigens
NZ590115A (en) Monoclonal antibodies having homosubtype cross -neutralization properties against influenza a viruses subtype h1
IL203869A (en) Method for the manufcture of a preparation comprising virus or viral antigens and various aspects related thereto, uses thereof and a split virus vaccine preparation obtained by the method
WO2012096994A3 (en) Antibodies directed against influenza
WO2009035420A8 (en) Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
WO2010132604A3 (en) Neutralizing molecules to influenza viruses
BRPI0811499A2 (en) METHODS FOR PURIFYING A VIRAL VIRUS OR ANTIGEN, AND FOR PREPARING A VACCINE AGAINST A VIRAL VIRUS OR ANTIGEN.
WO2012024632A3 (en) Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e
WO2013059524A3 (en) Antibodies directed against influenza
WO2011046623A3 (en) Hiv-1 antibodies
WO2014052378A8 (en) Subunit immersion vaccines for fish
EA201001045A1 (en) MODIFIED FLU VIRUS
IL193397A0 (en) Hpv antigens, vaccine compositions, and related methods
WO2009115917A3 (en) Improvements in preparation of influenza virus vaccine antigens
HK1203524A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses h3n2h2n2 b
WO2009155489A3 (en) Compositions and methods for treating influenza
EP1989316A4 (en) Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions
WO2008147496A3 (en) Neuraminidase-deficient live influenza vaccines
WO2010095041A3 (en) Compositions, methods, and kits for treating influenza viral infections
WO2009035412A8 (en) Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof
EP1862537A4 (en) Cell line culturable without aminal-derived component, method for establishment thereof, method for production of virus using the cell line and method for production of vaccine
WO2010040572A3 (en) Antibodies against h5n1 influenza viruses
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
WO2011098778A3 (en) Peptides for vaccines against birch allergy
MX363464B (en) Influenza h5 vaccines.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09748707

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09748707

Country of ref document: EP

Kind code of ref document: A2